PROCESS FOR TREATING HUMAN TRANSPIRATION USING A CATION AND AN ANION IN PRESENCE OF A MODULATOR

This invention relates to a cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, which includes the use of at least one cation Xn+ of valency n, of at least one anion Ym" of valency m and of at least one modulating agent.

This invention in particular relates to a cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, which includes

(i) either the mixing just before use of at least one composition A and of at least one composition B; said compositions A and B being packaged separately followed by the application of the resulting mixture on the surface of the skin;

(ii) or the application on the surface of the skin simultaneously or sequentially of at least one composition A and of at least one composition B packaged separately;

(iii) or the application on the surface of the skin of a composition comprising in the same support at least one composition A and of at least one composition B;

- said composition A comprising in a cosmetically acceptable medium at least one cation Xn+ of valency n;

said composition B comprising in a cosmetically acceptable medium at least one anion Ym" of valency m;

the mixture of said composition A with said composition B comprising in addition at least one modulating agent.

The underarms as well as certain other parts of the body are generally the place of several discomforts that can stem directly or not from perspiration problems. These phenomena often cause unpleasant and uncomfortable sensations which are primarily due to the presence of sweat resulting from perspiration that can, in certain cases, make the skin moist and wet clothing, in particular at the level of the underarms or the back, as such leaving visible traces. Moreover, the presence of sweat can generate the discharging of body odors that are most of the time unpleasant. Finally, during the evaporation thereof, sweat can also leave behind salts and/or proteins on the surface of the skin which can cause white traces on clothing. Such discomforts are to be taken into account including in the case of moderate perspiration.

In the cosmetics field, it is as such well known to use a topical application, antiperspirant products containing substances that have for effect to limit and even suppress the sweat flow so as to remedy the problems mentioned hereinabove. These products are in general available in the form of roll-on, sticks, aerosol or spray.

The antiperspirant substances are in general comprised of aluminum and/or zirconium hydrochlorides. These substances make it possible to reduce the sweat flow by forming a plug on the sweat channel.

However, the use of these substances at high concentrations in order to obtain good effectiveness causes difficulties in terms of the formulation.

In addition, it has been observed that the antiperspirant effectiveness of these substances is limited when they are used alone. This implies that these substances need to be applied several times on the skin in order to obtain a satisfactory effective antiperspirant effect.

Finally, these antiperspirant substances can also leave traces when they are applied which has the consequence of staining clothing.

In order to overcome all of these disadvantages mentioned hereinabove, it has been proposed to seek other effective active substances, that are tolerated by the skin and easy to formulate.

It has already been proposed in application US20070196303 to use cations of the calcium type and/or strontium type in the presence of a buffer comprised of an amino acid and of a betaine in order to reinforce the activity of the aluminum hydrochlorides.

It has also already been proposed in application WO0010512 to use cations of the calcium type in the presence of an acid solution with an amino acid and/or hydroxy acid base in order to reinforce the activity of aluminum and/or zirconium salts. The presence of aluminum and/or zirconium salts remains mandatory in these antiperspirant formulations.

As an alternative to the aluminum and/or zirconium hydrochlorides, it has already been proposed in patent WO2013/013902 an antiperspirant multi-component agent comprising a first component comprised of a cosmetic composition A and a second component comprised of a cosmetic composition B different from the cosmetic composition A, intended to be mixed before application on the skin or to be applied on the skin simultaneously, separately or delayed over time, said cosmetic composition A comprising a multivalent cation halide, and said composition B comprising a non-nitrogen-containing salt of an anion. The application mode is however rather restrictive for the consumer.

As such there is therefore a real need to implement on the skin an agent intended for the treatment of human perspiration that does not have all of the disadvantages described hereinabove, i.e. that provides a satisfactory antiperspirant effect, in particular in terms of effectiveness and resistance to sweat, and that is tolerated well by the skin. Furthermore, there is a need for such an agent intended for the treatment of human perspiration, that can be used alone or in association with an additional antiperspirant agent. Finally, such an agent must be able to be formulated in a way that is stable in storage.

The Applicant discovered surprisingly that this objective could be achieved by having recourse to a cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, that includes the use of at least one cation Xn+ of valency n, of at least one anion Ym" of valency m and of at least one modulating agent.

This invention therefore relates to a cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, that includes the use of at least one cation Xn+ of valency n, of at least one anion Ym" of valency m and of at least one modulating agent.

When the cation Xn+ of valency n, the anion Ym" of valency m and the modulating agent are formulated in an anhydrous medium, they can be present within the same composition (i.e. a single composition).

Alternatively, they can be formulated in two different compositions, one comprising the cation Xn+ of valency n (composition A), and the other comprising the anion Ym" of valency m (composition B). The modulating agent can however be present in the composition A and/or in the composition B. According to an alternative, the modulating agent is not introduced into the composition A or into the composition B, but it is generated during the mixture between the compositions A and B.

When the cation Xn+ of valency n, the anion Ym" of valency m and the modulating agent are formulated in an aqueous medium (i.e. comprising an aqueous phase, for example an aqueous solution or an oil-in-water or water-in-oil emulsion), the cation is necessarily formulated in a composition separate from the anion.

As such in this embodiment, preferably:

- the cation Xn+ of valency n is present in a composition A;

- the anion Ym" of valency m is present in a composition B, the compositions A and B being different, and the composition A and/or B comprising at least an aqueous phase; and

- the modulating agent is present in the composition A and/or in the composition B. According to an alternative, the modulating agent is not introduced into the composition A or into the composition B, but it is generated during the mixture between the compositions A and B.

Preferably, this invention relates to a cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, that includes (i) either the mixing just before use of at least one composition A and of at least one composition B, said compositions A and B being packaged separately, followed by the application of the resulting mixture on the surface of the skin;

(ii) or the application on the surface of the skin simultaneously or sequentially of at least one composition A and of at least one composition B packaged separately; (iii) or the application on the surface of the skin of a composition comprising in the same support at least one composition A and of at least one composition B;

said composition A comprising in a cosmetically acceptable medium at least one cation Xn+ of valency n;

said composition B comprising in a cosmetically acceptable medium at least one anion Ym" of valency m;

the mixture of said composition A with said composition B comprising in addition at least one modulating agent.

According to a first embodiment, the modulating agent can be present in the composition A and/or in the composition B.

According to a second embodiment, it can also not be present in the composition A or in the composition B, but be generated in situ following the mixture of said compositions A and B.

Such a method according to the invention is effective in the treatment of human perspiration. Furthermore, the compositions A and B are stable in storage.

This invention also relates to a cosmetic composition, in particular for the treatment of human perspiration and optionally body odors resulting from the perspiration, ready-to-use, that includes, in a cosmetically acceptable medium, at least one cation Xn+ of valency n, of at least one anion Ym" of valency m and of at least one modulating agent. This composition is called "ready-to-use composition" in this application.

The term "ready to use" means that the composition is applied on the surface of the skin in a very short period of time following the preparation thereof, for example from a few seconds to a few minutes following the preparation thereof. Typically, the time between the mixing of the cation(s) Xn+ of valency n, anion(s) Ym" of valency m and modulator(s) and the application on the skin is from 0 to 30 minutes, preferably from 0 to 10 minutes, preferably from 0 to 1 minute, and preferably from 0 to 30 seconds.

The term "antiperspirant agent" means any substance or any composition that has for effect to reduce sweat flow and/or reducing the damp sensation on the skin associated with human sweat and/or to mask human sweat.

The term "cosmetically acceptable medium" means a medium compatible with the skin and/or integuments or mucosa thereof, having a pleasant color, odor and texture and not giving rise to unacceptable discomfort (such as tightness), liable to dissuade the consumer from using the composition.

Said cosmetically acceptable medium is also a medium that does not leave any traces during the application thereof, and that does not as such stain clothing. Said cosmetically acceptable medium can be anhydrous or include an aqueous phase. Preferably, it comprises an aqueous phase. Preferably in particular, the cosmetically acceptable medium of the ready-to-use composition comprises an aqueous phase.

The term "cation Xn+" means an ionic compound preferably inorganic comprising one or several positive charges; the valency n indicating the number of positive charges.

The term "anion Ym"" means an ionic compound preferably inorganic comprising one or several negative charges; the valency m indicating the number of negative charges.

The term "sequential" means a successive administration.

The term "same support" means that the compositions A and B according to the invention are present in the same packaging, in particular in a two-compartment packaging that allows for the simultaneous applications of the compositions A and B.

CATION X'

The cations Xn+ in accordance with the invention are chosen preferably from the multivalent inorganic cations of which the valency n is by definition at least 2, preferably 2, 3 or 4.

The multivalent inorganic cations Xn+ are preferably chosen from:

- the alkali earth cations such as Magnesium (Mg2+) or Calcium (Ca2+); and

- the transition metal cations such as Titanium (Ti4+), Manganese (Mn2+, Mn3+, Mn4+), Iron (Fe2+, Fe3+), copper (Cu2+), Zinc (Zn2+) or Zirconium (Zr4+).

The multivalent inorganic cations Xn+ are preferably chosen from the alkali earth cations.

The preferred alkali earth cations will be chosen from Magnesium (Mg2+) and Calcium (Ca2+).

The preferred transition metal cations will be chosen from Zinc, Manganese, Iron and Titanium.

The cations in accordance with the invention are introduced into the single anhydrous composition, into the composition A or into the ready-to-use composition, in the form of water soluble salts. In terms of this invention, the term "water soluble salt" means any salt that, after having been completely dissolved with stirring at 0.5% in a solution of water at a temperature of 25°C, leads to a solution comprising a quantity of insoluble salt less than 0.05% by weight.

Preferably, the water soluble salts of cation Xn+ are chosen from halides, sulfates and carboxylates.

Indeed, among the salts of cation Xn+ that can be used according to the invention, mention can be made of halides. As halides, fluorides (Fluorine), chlorides (Chlorine), bromides (Bromine) and iodides (Iodine) and more particularly chlorides will be used.

Among the water soluble salts of cations Xn+ that can be used according to the invention, mention can also be made of carboxylic acid salts or carboxylates such as acetates, propionates, pyrrolidone carboxylates (or pidolates); polyhydroxyl carboxylic acid salts such as gluconates, heptagluconates, keto-glutonates; mono or polycarboxylic hydroxy acid salts such as citrates, lactates; amino acid salts such as aspartates, glutamates and ascorbic acid salts. Acetate salts, lactate salts or aspartate salts will be used more particularly.

Mention can also be made of sulfates such as magnesium sulfate, ferric sulfates, zinc sulfates.

As examples of salts of cation Xn+ in accordance with the invention, mention can be made of Magnesium chloride, Calcium chloride, Calcium pidolate, Calcium aspartate, Calcium gluconate, Calcium glutamate, Calcium heptagluconate, Calcium propionate, Calcium 2-cetogluconate, Calcium lactate, Calcium ascorbate, Calcium citrate, Magnesium acetate, Magnesium pidolate, Magnesium gluconate, Magnesium glutamate, Magnesium heptagluconate, Magnesium 2-

cetogluconate, Magnesium lactate, Magnesium ascorbate, Magnesium citrate, Magnesium aspartate or Manganese gluconate.

Mention can also be made of sulfates such as Magnesium sulfate.

Calcium chloride, Magnesium chloride, Calcium acetate, Magnesium lactate, Calcium citrate and Magnesium citrate will preferably be chosen.

Preferably, the composition A comprising at least one cation Xn+ according to the invention comprises an aqueous phase and has a pH between 2 and 6, preferably between 3 and 5. If necessary, the pH is adjusted with a cosmetically acceptable organic or mineral acid or base. Such an acid or such a base are those conventionally used in cosmetics.

The composition A comprises at least one cation Xn+ of valency n, and does not contain any anion(s) Ym" of valency m as counter ion(s).

Preferably, the composition A comprises at least one cation Xn+ of valency n in a content between 0.5% and 30% by weight of the total weight of the composition A, preferably between 1 % and 25% by weight.

Likewise, preferably, the single anhydrous composition comprises at least one cation Xn+ of valency n in a content between 0.5% and 30% by weight of the total weight of the composition, preferably between 1 % and 25% by weight.

According to a particular embodiment of the invention, the composition A comprises a mixture of cations Xn+ of valency n, and does not contain any anion(s) Ym" of valency m.

According to a preferred embodiment of the invention, the composition A comprises a cation Xn+ of valency n, and does not contain any anion(s) Ym" of valency m.

According to another embodiment of the invention, the "ready-to-use composition" comprises a cation Xn+ of valency n, and one or several anion(s) Ym" of valency m, preferably one anion Ym" of valency m.

ANION Ym"

The anions Ym" in accordance with the invention preferably have a valency m of at least 2, preferably 2, 3 or 4. They are preferably inorganic. They are chosen preferably from carbonate (C032"), hydrogenocarbonate (HC03") phosphate (P043" ), polyphosphates such as diphosphate P2O74" (also called pyrophosphate), triphosphate P3O105", phosphonate (P033"), hydrogenophosphate (HP042"), sulfate (S042"), sulfonate (S032"), hydrogenosulfate (HS04"), hydrogenosulfonate (HS03"), silicate (Si032"). Hydrogenophosphate or hydrogenocarbonate will be used more particularly.

The anions Ym" in accordance with the invention are introduced into the single anhydrous composition, into the composition B or into the ready-to-use composition, in the form of a water soluble salt. In terms of this invention, the term "water soluble salt" of an anion Ym" means any salt that, after having been completely dissolved with stirring at 0.5% in a solution of water at a temperature of 25°C, leads to a solution comprising a quantity of insoluble salt less than 0.05% by weight.

The water soluble salt of anion Ym" can be chosen for example from:

alkali metal salts such as potassium, sodium, and

ammonium salts, such as alkanolamine salts (in particular mono-, di- or tri-alkanolamine), comprising one to three CrC4 hydroxyalkyl radicals, identical or not.

Among the alkanolamine compounds, mention can be made of monoethanolamine, diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, N-dimethylaminoethanolamine, 2-amino-2-methyl-1 -propanol, triisopropanolamine, 2-amino-2-methyl-1 ,3-propanediol, 3-amino-1 ,2-propanediol, 3-dimethylamino-1 ,2-propanediol, tris-hydroxymethylaminomethane.

Preferably, the anion Ym"will be introduced in the form of an alkali metal salt, in particular a sodium or potassium salt.

Among the preferred salts of anion Ym", mention can be made of Na2C03, K2C03, NaHC03, KHC03, Na3P03, Na2HP04, NaH2P04, Na2H2P207, Na4P207, K2HP04, KH2P04, K2H2P207, K4P207, Na2S04, K2S04. Hydrogenocarbonate of sodium NaHC03, or hydrogenophosphate disodium Na2HP04 will preferably be used.

The molar ratio between the cation or cations Xn+ and the anion or anion Ym" varies preferably from 10 :1 to 1 :10 and more preferably from 4 :1 to 1 :4.

The total concentration in cation(s) Xn+ and in anion(s) Ym" varies preferably from 1 to 70% by weight and more preferably from 2 to 50% by weight of the total weight of the compositions A and B (or in the ready-to-use composition or in the single anhydrous composition).

The composition B comprises at least one anion Ym" of valency m, and does not contain any cation Xn+ of valency n as counter ion.

Preferably, the composition B comprises at least one anion Ym" of valency m in a content between 0.5% and 30% by weight of the total weight of the composition B, preferably between 0.7% and 25% by weight.

Likewise, preferably, the single anhydrous composition comprises at least one anion Ym" of valency m in a content between 0.5% and 30% by weight of the total weight of the composition B, preferably between 0.7% and 25% by weight.

According to a particular embodiment of the invention, the composition B comprises a mixture of anions Ym" of valency m, and does not contain any cation(s) Xn+ of valency n.

According to a preferred embodiment of the invention, the composition B comprises anions Ym" of valency m, and does not contain any cation(s) Xn+ of valency n.

According to another embodiment of the invention, the "ready-to-use composition" comprises an anion Ym" of valency m, and one or several cation(s) Xn+ of valency n, preferably one cation(s) Xn+ of valency n.

MODULATORS

As indicated hereinabove, according to a first embodiment, the modulating agent(s) can be present in the composition A and/or in the composition B. Preferably, the modulating agent(s) are present in the composition A.

According to a second embodiment, it can also not be present in the composition A or in the composition B, but be generated in situ following the mixture of said compositions A and B.

The modulating agent in accordance with the invention can be chosen from the complexing agents of the cation(s) Xn+ and the complexing agents of the anion(s) Ym". Preferably, the modulating agent in accordance with the invention can be chosen from the complexing agents of the cation(s) Xn+.

The modulating agent in accordance with the invention is different from the anion(s) Ym" and from the cation(s) Xn+.

In particular, it can be chosen from:

- the mono or polycarboxylic acids (preferably di- or tricarboxylic), optionally hydroxylated (i.e. hydroxyacids), in free or salified form, such as propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid,

- the amino carboxylic acids in free or salified form such as aspartic acid, glutamic acid, serine, alanine, dehydroalanine and the oligomers thereof, iminosuccinic acid and the derivatives thereof, ethylene diamine tetraacetic acid,

- monosaccharides, oligosaccharides, polysaccharides and the derivatives thereof. Preferably, the monosaccharides are chosen from glucose, galactose, mannose, xylose, lyxose, fucose, arabinose, rhamnose, ribose, deoxyribose, quinovose, fructose, sorbose, talose, threose and erythrose. Preferably, the oligosaccharides comprise from 2 to 6 monosaccharide units, and are preferably chosen from trehalose, lactose, maltose and cellobiose. The derivatives are preferably chosen from glucuronic and lactobionic acid. Finally, the polysaccharides are preferably chosen from alginates, chitosans and pectins,

- ascorbic acid,

- phytic acid,

- polymers or copolymers of carboxylic acids in free or salified form such as the products sold under the name SOKOLAN CP42, CP44 by BASF,

- polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid such as for example the polymers mentioned in patents WO 921 6462, WO 9403527 Srchem Incorp. and in particular a solution sodium polyaspartate at 30% in water such as the product sold under the trade name AQUADEW SPA-30 by Ajinomoto; polyglutamic acid,

- polymers or copolymers of maleic or itaconic acid,

- polymers or copolymers of carboxymethylinulin.

Among the preferred modulators, when they must be added, mention will be made of amino carboxylic acids in free or salified form, mono or polycarboxylic acids

optionally hydroxylated in free or salified form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid, or the polymers or copolymers of carboxylic acids in free or salified form.

Citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid, in free or salified form, or a polymers or copolymers of carboxylic acids optionally amino will be used more particularly.

According to a particular embodiment of the invention, the composition A or the composition B or the "ready-to-use composition" or the single anhydrous composition, comprise a mixture of modulating agents, preferably two modulating agents.

More preferably, as modulating agents will be used a mixture of citric acid in free form and of citric acid in salified form (or citrate), in particular a mixture of citric acid and of sodium citrate. More preferably, the weight ratio (citric acid in free form): (citric acid in salified form) is between 1 :4 and 1 :2.

The modulating agent(s) in accordance with the invention can be present in the composition A and/or B (or in the ready-to-use composition or in the single anhydrous composition) in a content between 0.01 and 30% by weight of the total weight of the composition A and/or B (or of the ready-to-use composition or of the single anhydrous composition), preferably between 0.03 and 10% by weight.

Preferably, the weight ratio between the modulating agent(s) and the salt(s) of cation(s) Xn+ is between 0.01 and 1 .5, preferably between 0.03 and 1 .

Preferably, the composition resulting from the mixture of the compositions A and B (or the ready-to-use composition) has a pH between 5 and 8.

METHOD OF APPLICATION

In order to obtain an antiperspirant effect on the skin, according to a first alternative of the method for the treatment of perspiration of the invention (embodiment (i)), the composition A comprising at least one cation Xn+ and the composition B comprising at least one anion Ym" will be packaged separately and are mixed just before use (extemporaneous mixture) then the mixture obtained as such is applied on the surface of the skin to be treated.

According to a second alternative of the antiperspirant method of the invention (embodiment (ii)), the composition A comprising at least one cation Xn+ and the composition B comprising at least one anion Ym" will be packaged separately and applied simultaneously or sequentially on the surface of the skin to be treated. According to this alternative, when the compositions A and B are applied sequentially, the interval of time separating the application of the composition A from the application B can vary from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour.

In order to obtain an antiperspirant effect on the skin, according to a third alternative of the method for the treatment of perspiration of the invention (embodiment (iii)), on the surface of the skin is directly applied a composition

comprising in the same support the composition A containing at least one cation Xn+, the composition B containing at least one anion Ym" and at least one modulator.

The compositions A and B can, each one independently, be anhydrous or comprise an aqueous phase. They will preferably be in the form of aqueous solutions, alcoholic or hydroalcoholic solutions.

With regards in particular to the aforementioned embodiment (iii), the compositions A and B can be for example packaged in a device comprising at least two compartments containing respectively the composition A and the composition B such as a twin-tubes, a pump bottle with two compartments, an aerosol device comprising two compartments that can include one or more outlet orifices (mono-nozzle or double-nozzle), a device provided with a perforated wall such as a grid comprising two compartments; a device comprising two compartments each provided with a ball applicator (multi-ball roll-on); a double-stick.

Preferably, the compositions A and B will be applied sequentially and even more preferably, the composition A comprising at least one cation Xn+ will be applied first.

Preferably, the compositions A and B will be applied sequentially and even more preferably, the composition A comprising at least one cation Xn+ and at least one modulating agent will be applied first.

DOSAGE FORMS

The compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) can independently of one another be presented in any of the dosage forms conventionally used for topical application and particularly in the form of aqueous gels, aqueous or hydroalcoholic solutions. The compositions A and/or B (or the ready-to-use composition) can also be anhydrous. They may also, by the addition of a fatty or oil phase, be in the form of dispersions such as lotion, emulsions of liquid or semi-liquid consistency such as milk, obtained by dispersing a fatty phase in an aqueous phase (O/W) or conversely (W/O), or suspensions or emulsions of soft, semi-solid or solid consistency such as cream or gel, or multiple emulsions (W/O/W or 0/W/O), microemulsions, ionic and/or non-ionic type vesicle dispersions, or wax/aqueous phase dispersions. These compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) are prepared according to the usual methods.

The compositions A and/or B may be particularly packaged in pressurized form in an aerosol device or in a pump bottle; packaged in a device equipped with a perforated wall particularly a grid; packaged in a device equipped with a roll-on applicator; packaged in stick form, in loose or compact powder form. In this respect, they contain the ingredients generally used in this type of products and well-known to those skilled in the art.

According to another particular embodiment of the invention, the compositions A and/or B or the ready-to-use composition or the single anhydrous composition, can be solid in particular in the form of a stick; in loose or compact powder form.

The term "solid composition" denotes that the measurement of the maximum force measured by means of texturometric analysis on inserting a probe in the sample of formula should be at least equal to 0.25 Newton, in particular at least equal to 0.30 Newton, particularly at least equal to 0.35 Newton, assessed under precise measurement conditions as follows.

To take texturometric measurements, the formulas are poured when heated into jars 4 cm in diameter and 3 cm at the bottom. Cooling is performed at ambient temperature. The hardness of the formulas produced is measured after waiting 24 hours. The jars containing the samples are characterized by means of texturometric analysis using a texturometer such as that marketed by Rheo TA-XT2, according to the following protocol: a 5 mm diameter stainless steel ball type probe is brought into contact with the sample at a speed of 1 mm/s. The measurement system detects the interface with the sample with a detection threshold equal to 0.005 Newtons. The probe is inserted 0.3 mm into the sample, at a rate of 0.1 mm/s. The measurement apparatus records the progression of the compression force measured over time, during the penetration phase. The hardness of the sample corresponds to the mean of the maximum values of the force detected during penetration, for at least 3 measurements.

The invention also relates to a method for the cosmetic treatment of human perspiration, and optionally body odors associated with human perspiration, consisting in applying on the surface of the skin, in particular on the surface of the underarms, an effective quantity of the composition A and an effective quantity of the composition B; or an effective quantity of the ready-to-use composition; or an effective quantity of the single anhydrous composition.

The application time of the composition A and/or B (or of the ready-to-use composition or of the single anhydrous composition) on the surface of the skin can vary from 0.5 to 10 seconds, preferably from 1 to 5 seconds.

These compositions A and B (or the ready-to-use composition or the single anhydrous composition) can be applied several times on the surface of the skin. They can be applied several times, over one day or over several days.

Another object of this invention is an aerosol device constituted by a first receptacle comprising a pressurized composition A, a second receptacle comprising a pressurized composition B and by a dispensing means of the mixture of said composition.

The dispensing means, forming part of the aerosol device, generally consist of a dispensing valve controlled by a dispensing head, in turn comprising a nozzle via which the pressurized compositions A and B are sprayed as a mixture. The receptacle containing the pressurized compositions A and B may be opaque or transparent. It may be made of glass, polymeric or metal material, optionally coated with a layer of protective varnish.

Another object of this invention is an aerosol device comprised of a receptacle comprising a pressurized anhydrous composition comprising, in a cosmetically

acceptable medium, at least one cation Xn+ of valency n, at least one anion Ym" of valency m and at least one modulating agent; and by a dispensing means of the mixture of said composition.

The dispensing means, forming part of the aerosol device, generally consist of a dispensing valve controlled by a dispensing head, in turn comprising a nozzle via which the pressurized anhydrous composition is sprayed. The receptacle containing the pressurized anhydrous composition may be opaque or transparent. It may be made of glass, polymeric or metal material, optionally coated with a layer of protective varnish.

The compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) can also comprise at least one deodorant agent and/or at least one additional antiperspirant agent.

The term "deodorant agent" denotes in the context of the present invention any agent, alone, with the effect of masking, absorbing, enhancing and/or reducing the unpleasant odor resulting from the decomposition of human sweat.

By way of illustration of these additional deodorant agents can in particular be mentioned bacteriostatic agents or bactericidal agents acting on germs of underarm odor, such as 2,4,4'-trichloro-2'-hydroxydiphenylether (©Triclosan), 2,4-dichloro-2'-hydroxydiphenylether, 3',4',5'-trichlorosalicylanilide,1 -(3',4'-dichlorophenyl)-3-(4'-chlorophenyl)urea (©Triclocarban) or 3,7,1 1 -trimethyldodeca-2,5,10-trienol (©Farnesol); quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; polyols such as those of the glycerin type, 1 ,3-propanediol (ZEMEA PROPANEDIOL® sold by Dupont Tate and Lyle Bioproducts), 1 ,2-decanediol (Symclariol® from Symrise); glycerin derivatives such as for example Caprylic/Capric Glycerides (CAPMUL MCM® from Abitec), Caprylate or glyceryl caprylate (DERMOSOFT GMCY® and DERMOSOFT GMC® respectively from STRAETMANS), Polyglyceryl-2 Caprate (DERMOSOFT DGMC® from STRAETMANS), biguanide derivatives such as polyhexamethylene biguanide salts; chlorhexidine and salts thereof; 4-Phenyl-4,4-dimethyl-2butanol (SYMDEO MPP® from Symrise); cyclodextrins; or alun.

The additional deodorant agents can be present preferably in the compositions according to the invention in mass concentrations ranging from 0.01 % to 10% by weight in relation to the total weight of the composition.

The term "antiperspirant agent" denotes any substance, alone, with the effect of reducing sweat flow, reducing the damp sensation on the skin associated with human sweat, masking human sweat.

By way of illustration of these additional antiperspirant agents, mention can be made in particular of aluminum and/or zirconium antiperspirant salts or complexes, preferably chosen from aluminum halohydrates; aluminum and zirconium halohydrates, zirconium hydroxychloride and aluminum hydroxychloride complexes with or without an amino acid such as those described in patent US-3792068.

Among the aluminum salts mention can be made in particular of aluminum chlorhydrate in activated or non-activated form, aluminum chlorohydrex, aluminum chlorohydrex polyethyleneglycol complex, aluminum chlorohydrex propyleneglycol complex, aluminum dichlorohydrate, aluminum dichlorohydrex polyethyleneglycol complex, aluminum dichlorohydrex propyleneglycol complex, aluminum sesquichlorohydrate, aluminum sesquichlorohydrex polyethylene

glycol complex, aluminum sesquichlorohydrex propyleneglycol complex, aluminum sulfate buffered by aluminum and sodium lactate.

Among the aluminum and zirconium salts mention can be made in particular of aluminum zirconium octachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium trichlorohydrate.

Zirconium hydroxychloride and aluminum hydroxychloride complexes with an amino acid are generally known under the name ZAG (when the amino acid is glycine). Among these products, mention can be made of the complexes of aluminum zirconium octachlorohydrex glycine, aluminum zirconium pentachlorohydrex glycine, aluminum zirconium tetrachlorohydrex glycine and aluminum zirconium trichlorohydrex glycine.

Aluminum sesquichlorohydrate is in particular sold under the trade name REACH 301 ® by SUMMITREHEIS.

Among the aluminum and zirconium salts, mention can be made of the complexes of zirconium hydroxychloride and aluminum hydroxychloride with an amino acid such as glycine having for name INCI : ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY for example that sold under the trade name REACH AZP-908-SUF® by SUMMITREHEIS.

Use will be made more particularly of aluminum chlorhydrate in activated or non-activated form sold under the trade names LOCRON S FLA®, LOCRON P, LOCRON L.ZA by CLARIANT; under the trade names MICRODRY ALUMINUM CHLOROHYDRATE®, MICRO-DRY 323®, CHLORHYDROL 50, REACH 103, REACH 501 by SUMMITREHEIS; under the trade name WESTCHLOR 200® by WESTWOOD; under the trade name ALOXICOLL PF 40® by GUILINI CHEMIE; CLURON 50%® by INDUSTRIA QUIMICA DEL CENTRO; CLOROHIDROXIDO ALUMINIO SO A 50%® by FINQUIMICA.

As another antiperspirant agent, mention can be made of the particles of expanded perlite such as those obtained by the method of expansion described in the patent US 5,002,698.

Preferably, the compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) comprise less than 5% by weight of aluminum salt, preferable less than 3% by weight, preferably less than 1 % by weight.

Preferably, the compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) are totally free of aluminum salt.

In the case where the compositions A and B are mixed extemporaneously, the dosage forms will preferably be aqueous, alcoholic or hydroalcoholic solutions.

AQUEOUS PHASE

The compositions A and/or B (or the ready-to-use composition) can comprise at least one aqueous phase. They are formulated particularly in aqueous lotions or in a water-in-oil emulsion, an oil-in-water emulsion, or in a multiple emulsion (triple oil-in-water-in-oil or water-in-oil-in-water emulsion) (such emulsions are known and described for example by C. FOX in "Cosmetics and Toiletries" - November 1986 - Vol 101 - pages 101 -1 12).

The aqueous phase of said compositions A and/or B (or the ready-to-use composition) contains water and generally other solvents soluble in water or miscible with water. The water-soluble or miscible solvents comprise short-chain mono-alcohols for example CrC4 such as ethanol, isopropanol; diols or polyols such as ethyleneglycol, 1 ,2-propyleneglycol, 1 ,3-butylene glycol, hexyleneglycol, diethyleneglycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monomethylether, triethylene glycol monomethylether and sorbitol. Propyleneglycol and glycerin, propane 1 ,3 diol shall more particularly be used.

EMU LSI FIE RS

a) Oil-in-water emulsifiers

The compositions A and/or B (or the ready-to-use composition) can comprise at least one surfactant.

The surfactants can be of any sort usually used in cosmetics, such as anionic surfactants, cationic surfactants, amphoteric surfactants or non-ionic surfactants.

Preferably, non-ionic surfactants are used such as:

- C8-C30 (preferably C12-C18) polyoxyethylenated fatty alcohols, having in particular from 2 to 100 moles of ethylene oxide, such as oxyethylene ether of cetearylic alcohol with 30 oxyethylene groups (CTFA name "Ceteareth-30"), oxyethylene ether of stearylic alcohol with 20 oxyethylene groups (CTFA name "Steareth-20") such as BRIJ 78 marketed by UNIQEMA, or oxyethylene ether of cetearylic alcohol with 33 oxyethylene groups (CTFA name "Ceteareth-33") ;

- C8-C30 fatty alcohol and sugar ethers, in particular alkyl (C8-C30) (poly)glucosides, alone or in mixtures with alcohols, such as the mixture of cetylstearyl alcohol and of cocoglucoside sold under the name MONTANOV 82® by Seppic, the mixture of arachidylic alcohol and of behenyl alcohol with arachidylglucoside sold under the name MONTANOV 802® by Seppic, the mixture of myristyl alcohol and of myristylglucoside sold under the name MONTANOV 14® by Seppic, the mixture of cetylstearylic alcohol and of cetylstearylglucoside sold under the name MONTANOV 68® by Seppic, the mixture of C14-C22 alcohol with C12-C20 alkylglucoside sold under the name MONTANOV L® by Seppic, the mixture of cocoalcohol and cocoglucoside sold under the name MONTANOV S® by Seppic or the mixture of isostearyl alcohol and isostearylglucoside sold under the name MONTANOV WO 18® by Seppic;

- ethers of polyethylene glycol, having in particular from 20 to 120 ethylene oxide motifs, and of C8-C30 fatty acid esters and of glucose or of methylglucose,

- C8-C30 fatty acid esters and sorbitan,

- C8-C30 fatty acid esters and polyoxyethylenated sorbitan, having in particular from 2 to 30 moles of ethylene oxide,

- C8-C30 polyoxyethylenated fatty acid esters and sorbitan, having in particular from 2 to 100 moles of ethylene oxide,

- C8-C30 fatty acid mono or di esters and glycerol,

- C8-C30 polyglycerolated fatty acid esters, having in particular from 2 to 1 6 moles of glycerol,

- C8-C30 fatty acid esters and polyethylene glycol, having in particular from 2 to 200 moles of ethylene oxide,

- C8-C30 fatty acid esters and of glucose or of alkyl(C1 -C2)glucose or sucrose, and

- mixtures thereof.

The surfactant(s) can be present in a quantity ranging from 0.1 to 10% by weight, with respect to the total weight of the composition A or B (or of the ready-to-use composition), preferably ranging from 0.2 to 5% by weight, and preferably ranging from 1 % to 4% by weight.

b) Water-in-oil emulsifiers

Among the emulsifiers that can be used in the water-in-oil emulsions or triple water-in-oil-in-water-in-oil emulsions or triple emulsions, mention can be made as an example of alkyl dimethicone copolyols having the following formula (I)

CH,

CH,

l "3 ?H2

CH3 - Si - -Si 0| Si - O- Si - CH, (I)

I

CH, CH,

R Ί R

a

wherein:

Ri designates a Ci2 to C2o linear or branched alkyl group and preferably Ci2 to C18;

R2 designates the group: -CnH2n-(-OC2H4-)x-(-OC3H6-)y-0-R3,

R3 represents a hydrogen atom or a linear or branched alkyl radical having from 1 to 12 carbon atoms;

a is an integer varying from 1 to about 500;

b designates an integer varying from 1 to about 500;

n is an integer varying from 2 to 12 and preferably from 2 to 5;

x designates an integer varying from 1 to about 50 and preferably from 1 to 30; y designates an integer varying from 0 to about 49 and preferably 0 to 29 with the reserve that when y is different from zero the ratio x/y is greater than 1 and preferably varies from 2 to 1 1 .

Among the preferred copolyol alkyldimethicone emulsifiers having formula (I), mention will be made particularly of CETYL PEG/PPG-10/1 DIMETHICONE and more particularly the mixture CETYL PEG/PPG-10/1 DIMETICONE AND DIMETHICONE (INCI name) such as the product sold under the trade name ABIL EM90 by GOLDSCHMIDT, LAURYL PEG/PPG-18/18 methicone and more particularly the mixture LAURYL PEG/PPG-18/18 methicone and DODECENE and POLOXAMER 407 such as the product sold under the trade name DOW CORNING 5200 FORMULATION AID by DOW CORNING or the mixture

(Polyglyceryl-4-stearate and Cetyl PEG/PPG-10 (and) Dimethicone (and) Hexyl Laurate) such as the product sold under the trade name ABIL WE09 by GOLDSCHMIDT.

Among the water-in-oil emulsifiers, mentioned can also be made of copolyol dimethicones having the following formula (II)

CH3 - CH, (N)

in which

R4 designates the group:-CmH2m-(-OC2H4-)s-(-OC3H6-)t-0-R5,

R5 designates a hydrogen atom or a linear or branched alkyl radical having from 1 to 12 carbon atoms;

c is an integer varying from 1 to about 500

d designates an integer varying from 1 to about 500,

n is an integer varying from 2 to 12 and preferably from 2 to 5,

s designates an integer varying from 1 to about 50, and preferably from 1 to 30; t designates an integer varying from 0 to about 50 and preferably from 0 to 30; provided that the sum s+t is greater than or equal to 1 .

Among these preferred copolyol dimethicone emulsifiers having formula (II) use will be made in particular of PEG-18/PPG-18 DIMETHICONE and more particularly the mixture CYCLO P E NTAS I LOXAN E (and) PEG-18/PPG-18 DIMETHICONE (INCI name) such as the product sold by Dow Corning under the trade name Silicone DC 5225 C or KF-6040 by Shin Etsu.

According to a particularly preferred embodiment, a mixture of at least one emulsifier having formula (I) and of at least one emulsifier having formula (II) will be used.

Use will more particularly be made of a mixture of PEG-18/PPG-18 Dimethicone and Cetyl PEG/PPG-10/1 DIMETHICONE, LAURYL PEG/PPG-18/18 methicone and even more particularly a mixture of (CYCLOPENTASILOXANE (and) PEG-18/PPG-18 Dimethicone) and of Cetyl PEG/PPG-10/1 DIMETICONE and Dimethicone or of (Polyglyceryl-4-stearate and Cetyl PEG/PPG-10 (and) Dimethicone (and) Hexyl Laurate) or the mixture LAURYL PEG/PPG-18/18 methicone and DODECENE and POLOXAMER 407.

Among the water-in-oil emulsifiers, mention can also be made of the non-ionic emulsifiers derived from fatty acids and from polyol, alkylpolyglycosides (APG), esters of sugars and the mixtures thereof.

As non-ionic emulsifiers derived from fatty acids and from polyol, it is possible to use in particular fatty acid esters and polyol, the fatty acid in particular having a C8-C24 alkyl chain, and the polyols being for example glycerol and sorbitan.

As fatty acid esters and polyol, mention can be made in particular of isostearic acid esters and polyols, stearic acid esters and polyols, and mixtures thereof, in particular isostearic acid esters and glycerol and/or sorbitan.

The polyol alkyl esters particularly include polyethyleneglycol esters such as PEG-30 Dipolyhydroxystearate such as the product marketed under the name Arlacel P135 by ICI.

The glycerol and/or sorbitan esters include, for example, polyglycerol isostearate, such as the product marketed under the name Isolan Gl 34 by Goldschmidt; sorbitan isostearate, such as the product marketed under the name Arlacel 987 by ICI ; sorbitan isostearate and glycerol, such as the product marketed under the name Arlacel 986 by ICI, the mixture of sorbitan isostearate and of polyglycerol isostearate (3 moles) marketed under the name Arlacel 1 690 by Unigema and mixtures thereof.

The emulsifier can also be chosen from alkylpolyglycosides having an HLB less than 7, for example those represented by the following general formula (1 ):

R-0-(G)x (1 )

wherein R represents a branched and/or unsaturated alkyl radical, comprising from 14 to 24 carbon atoms, G represents a reduced sugar comprising from 5 to 6 carbon atoms, and x designates a value ranging from 1 to 10 and preferably from 1 to 4, and G in particular designates glucose, fructose or galactose.

The unsaturated alkyl radical can comprise one or more ethylene unsaturations, and in particular one or two ethylene unsaturations.

As alkylpolyglycosides of this type, mention can be made of alkylpolyglucosides (G=glucose in the formula (1 )), and in particular the compounds having formula (I) wherein R represents more particularly an oleyl radical (C18 unsaturated radical) or isostearyl (C18 saturated radical), G designates glucose, x is a value varying from 1 to 2, in particular isostearyl-glucoside, oleyl-glucoside and mixtures thereof. This alkylpolyglucoside can be used in a mixture with a co-emulsifier, more especially with a fatty alcohol and in particular a fatty alcohol having the same fatty chain as that of alkylpolyglucoside, i.e. comprising from 14 to 24 carbon atoms and having a branched and/or unsaturated chain, and for example isostearylic alcohol when the alkylpolyglucoside is isostearyl-glucoside, and the oleyl alcohol when the alkylpolyglucoside is oleyl-glucoside, optionally in the form of a self-emulsifying composition, such as described for example in document WO-A-92/06778. It is possible to use for example the mixture of isostearyl-glucoside and of isostearylic alcohol, marketed under the name Montanov WO 18 by SEPPIC as well as the mixture octyldodecanol and octyldodecylxyloside marketed under the name FLUDANOV 20X by SEPPIC.

Mention can also be made of polyolefins with a succinic termination, such as polyisobutylenes with an esterified succinic termination and the salts thereof, in particular the diethanolamine salts, such as the products marketed under the names Lubrizol 2724, Lubrizol 2722 and Lubrizol 5603 by Lubrizol or the commercial product CHEMCINNATE 2000.

The total quantity in emulsifier(s) in the composition A or B (or in the ready-to-use composition) shall preferably have contents in activate material varying from 1 to 8% by weight and more particularly from 2 to 6% by weight relative to the total weight of the composition.

According to a particular embodiment of the invention, the compositions A and/or B (or in the ready-to-use composition) in the form of an emulsion can be prepared according to the reverse phase manufacturing technique. This technique is, in its principle, well known and in particular described in the article "Phase Inversion Emusification", by Th Forster et al, published in Cosmetics & Toiletries, vol. 106, December 1991 , pp 49-52. Its principle is as follows:

(i) In the presence of a suitable emulsifying system, with stirring, an oily phase on the one hand and an aqueous phase on the other hand are mixed, said mixture being carried out at a temperature greater than the phase inversion temperature (PIT) of the medium, in such a way as to obtain an emulsion of the water-in-oil type.

(ii) The temperature of the emulsion obtained as such is brought to a temperature less than said phase inversion temperature, this though which an ultrafine emulsion of the oil-in-water type is obtained.

(iii) Mineral nanopigments are then introduced during the implementation of the step (i) and/or at the end of the step (ii).

The suitable systems are emulsifiers of the non-ionic type and are chosen from polyoxyethylenated and/or polyoxypropylenated fatty alcohols (i.e. compounds obtained by a reaction between an aliphatic fatty alcohol, such as behenyl alcohol or cetyl alcohol, with ethylene oxide or propylene oxide or an ethylene oxide/propylene oxide mixture) and the esters of fatty acids and of polyols, optionally polyoxyethylenated and/or polyoxypropylenated (i.e. compounds obtained by a reaction of a fatty acid, such as stearic acid or oleic acid, with a polyol, such as for example an alkyleneglycol or glycerol or a polyglycerol, optionally in the presence of ethylene oxide or propylene oxide or an ethylene oxide/propylene oxide mixture), or mixtures thereof.

Moreover, and preferably, the emulsifying system retained will have a global HLB (HLB = Hydrophilic-Lipophilic Balance, in terms of Griffin; see J. Soc. Cosm. Chem. 1954 (vol 5), pp 249-256; balance between the hydrophilic nature and the lipophilic nature of the surfactant) ranging from 9.5 to about 1 1 .5, advantageously close to 10, in such a way as to make it possible to obtain a phase inversion at a temperature less than 90°C (TIP<90°C).

The content in emulsifying agent(s) is between 0.5 and 40% by weight and preferably between 2 and 10% by weight in relation to the total weight of the emulsion.

OILY PHASE

The compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) may contain at least one non-water-miscible organic liquid phase, known as a fatty phase. This generally includes one or a plurality of hydrophobic compounds rendering said phase non-miscible in water. Said phase is liquid (in the absence of a structuring agent) at ambient temperature (20-25 °C). Preferentially, the organic liquid phase non-miscible in water according to the invention is generally comprised of at least one volatile oil and/or one non-volatile oil and optionally at least one structuring agent.

Oil" means a liquid fatty body at ambient temperature (25°C) and atmospheric pressure (760mm Hg namely 105 Pa). The oil may be volatile or non-volatile.

The term "volatile oil" according to the invention denotes any oil capable of evaporating in contact with skin or keratin fiber, in less than one hour, at ambient temperature and atmospheric pressure. The volatile oils according to the invention are volatile cosmetic oils, which are liquid at ambient temperature, having a vapor pressure different to zero, at ambient temperature and atmospheric pressure, particularly ranging from 0.13 Pa to 40,000 Pa (10"3 at 300 mm Hg), particularly ranging from 1 .3 Pa to 13,000 Pa (0.01 to 100 mm Hg), and more specifically ranging from 1 .3 Pa to 1300 Pa (0.01 at 10 mm Hg).

The term "non-volatile oil" denotes an oil remaining on skin or keratin fiber at ambient temperature and atmospheric pressure for at least several hours and particularly having a vapor pressure less than 10"3 mm Hg (0.13 Pa).

The oil may be chosen from any physiologically acceptable and particularly cosmetically acceptable oils, in particular mineral, animal, plant, synthetic oils; in particular, volatile or non-volatile hydrocarbon and/or silicone and/or fluorinated oils and mixtures thereof.

More specifically, the term "hydrocarbon oil" denotes an oil essentially comprising carbon and hydrogen atoms and optionally one or a plurality of functions chosen from hydroxyl, ester, ether, carboxylic functions. Generally, the oil has a viscosity of 0.5 to 100,000 mPa.s, preferably from 50 to 50,000 mPa.s and more preferably from 100 to 300,000 mPa.s.

By way of examples of volatile oils suitable for use in the invention, mention may be made of:

volatile hydrocarbon oils chosen from hydrocarbon oils having 8 to 16 carbon atoms, and particularly petroleum-based C8-Ci6 isoalkanes (also referred to as isoparaffins) such as isododecane (also referred to as 2,2,4,4,6-pentamethylheptane), isodecane, isohexadecane, and for example the oils sold under the trade names Isopars or Permetyls, C8-Ci6 branched esters, iso-hexyl neopentanoate, and mixtures thereof. Further volatile hydrocarbon oils such as petroleum distillates, particularly those sold under the name Shell Solt by SHELL, may also be used; volatile linear alkanes such as those described in patent application of Cognis DE10 2008 012 457.

volatile silicones, such as for example volatile linear or cyclic silicone oils, particularly those having a viscosity < 8 centistokes (8 10"6 m2/s), and having in particular 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups having 1 to 10 carbon atoms. Mention may be made, as a volatile silicone oil suitable for use in the invention, in particular, of octamethyl cyclotetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, heptamethyl hexyltrisiloxane, heptamethyloctyl trisiloxane, hexamethyl disiloxane, octamethyl trisiloxane, decamethyl tetrasiloxane, dodecamethyl pentasiloxane

and mixtures thereof.

Mention may also be made of volatile alkyl trisiloxanes oils with general formula

in which R represents an alkyl group comprising 2 to 4 carbon atoms and in which one or several hydrogen atoms can be substituted by a fluorine or chlorine atom.

Among oils with general formula (I), mention may be made of:

3-butyl 1 ,1 ,1 ,3,5,5,5-heptamethyl trisiloxane,

3-propyl 1 ,1 ,1 ,3,5,5,5-heptamethyl trisiloxane, and

3-ethyl 1 ,1 ,1 ,3,5,5,5-heptamethyl trisiloxane,

corresponding to the oils having formula (I) for which R is respectively a butyl group, a propyl group or an ethyl group.

By way of examples of non-volatile oils suitable for use in the invention, mention may be made of:

plant-based hydrocarbon oils such as liquid fatty acid triglycerides having 4 to 24 carbon atoms such as heptanoic or octanoic triglycerides or wheat germ, olive oils, sweet almond, palm, rapeseed, cotton, coconut, alfalfa, poppy seed, pumpkin, squash, blackcurrant seed, evening primrose, millet, barley, quinoa, rye, safflower, candlenut, passiflora, musk rose, sunflower, corn, soybean, squash, grape seed, sesame, hazelnut, apricot, macadamia, castor, avocado oils, caprylic/capric acid triglycerides such as those sold by Stearineries Dubois or those sold under the trade names Miglyol 810, 812 and 818 by SASOL, jojoba oil, shea butter;

linear or branched hydrocarbons of mineral or synthetic origin, such as liquid paraffins and derivatives thereof, petroleum jelly, polydecenes, polybutenes, hydrogenated polyisobutene such as Parleam, squalane;

synthetic ethers having from 10 to 40 carbon atoms;

synthetic esters in particular fatty acids such as the oils having the formula R-iCOOR2 wherein R-i represents the residue of a linear or branched higher fatty acid comprising 1 to 40 carbon atoms and R2 represents a hydrocarbon chain, particularly branched containing 1 to 40 carbon atoms with R-i + R2 > 10 such as for example Purcellin oil (cetostearyl octanoate)), isononyl isononanoate, isopropyl myristate, isopropyl palmitate, C12 to C15 alcohol benzoate, hexyl laurate, diisopropyl adipate, 2-ethylhexyl palmitate, octyl-2-dodecyl stearate, octyl-2-dodecyl erucate, isostearyl isostearate, tridecyl trimellitate; octanoates, decanoates or ricinoleates of alcohols or polyalcohols such as propylene glycol

dioctanoate; hydroxylated esters, such as isostearyl lactate, octyl hydroxy stearate, octyldodecyl hydroxystearate, diisostearyl-malate, triisocetyl citrate; heptanoates, octanoates, decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate;

- fatty alcohols that are liquid at ambient temperature, with a branched and/or unsaturated carbon chain having 12 to 26 carbon atoms, such as octyldodecanol, isostearyl alcohol, 2-butyloctanol, 2-hexyl decanol, 2-undecylpentadecanol, oleic alcohol;

- higher fatty acids, such as oleic acid, linoleic acid, linolenic acid;

- fluorinated oils optionally partially hydrocarbon-based and/or silicone-based, such as fluorosilicone oils, fluorinated polyethers or fluorinated silicones, as described in document EP-A-847 752;

silicone oils, such as polydimethylsiloxanes (PDMS) which are non-volatile and linear or cyclic; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups which are pendant or at the end of the silicone chain, said groups having from 2 to 24 carbon atoms; phenylated silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyl-trisiloxanes or (2-phenylethyl)trimethylsiloxysilicates; and - mixtures thereof.

Solid fats

The compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) can comprise at least one solid fat chosen preferably from waxes and pasty fatty substances, and mixtures thereof and more particularly waxes.

Pasty fatty substances

The term "pasty fatty substance" (or pasty compound) refers to a lipophilic fatty compound having a reversible solid/liquid change of state, having an anisotropic crystalline organization in the solid state, and comprising a liquid fraction and a solid fraction at a temperature of 23 °C.

In other words, the initial melting point of the pasty compound may be less than 23°C. The liquid fraction of the pasty compound measured at 23°C may represent 9% to 97% by weight of the compound. This liquid fraction at 23°C preferably represents between 15% and 85%, more preferably between 40% and 85% by weight. According to the invention, the melting point is equivalent to the temperature of the most endothermic peak observed in thermal analysis (DSC) as described in the standard ISO 1 1357-3; 1999. The melting point of a paste or a wax may be measured using a differential scanning calorimeter (DSC), for example the calorimeter sold under the name "MDSC 2920" by 45 TA Instruments.

The measurement protocol is as follows: a 5 mg sample of pasty compound or wax (according to the case) placed in a crucible is subjected to a first temperature rise from -20°C to 100 °C, at a heating rate of 10°C / minute, and is then cooled from 100 °C to -20°C at a cooling rate of 10°C / minute and finally subjected to a second temperature rise from -20°C to 100 °C at a heating rate of 5 °C / minute. During the second temperature rise, the variation in the difference in power
CLAIMS

1. Cosmetic method for the treatment of human perspiration and optionally body odors resulting from the perspiration, comprising the use of at least one cation Xn+ of valency n, of at least one anion Ym" of valency m and of at least one modulating agent,

wherein said cation Xn+ is multivalent inorganic and chosen from:

(i) alkali earth cations, and

(ii) transition metal cations, and

said anion Ym" chosen preferably from carbonate (C032"), hydrogenocarbonate (HCO3"), phosphate (P043"), polyphosphates such as diphosphate P2O74", triphosphate P3O105", phosphonate (P033"), hydrogenophosphate (HP042"), sulfate (S042"), sulfonate (S032"), hydrogenosulfate (HS04"), hydrogenosulfonate (HS03") and silicate (S1O32").

2. Method according to claim 1 , characterized in that the cation Xn+ of valency n, the anion Ym" of valency m and the modulating agent are formulated in an anhydrous medium within the same composition.

3. Method according to claim 1 , characterized in that:

- the cation Xn+ of valency n is present in a composition A;

- the anion Ym" of valency m is present in a composition B, the compositions A and B being different;

- the modulating agent can be present in the composition A and/or in the composition B.

4. Method according to claim 1 , characterized in that:

- the cation Xn+ of valency n is present in a composition A;

- the anion Ym" of valency m is present in a composition B, the compositions A and B being different;

- the modulating agent is generated during the mixing between the compositions A and B.

5. Method according to one of claims 1 , 3 or 4, comprising:

(i) either the mixing just before use of at least one composition A and of at least one composition B, said compositions A and B being packaged separately, followed by the application of the resulting mixture on the surface of the skin;

(ii) or the application on the surface of the skin simultaneously or sequentially of at least one composition A and of at least one composition B packaged separately;

(iii) or the application on the surface of the skin of a composition comprising in the same support at least one composition A and of at least one composition B;

said composition A comprising in a cosmetically acceptable medium at least one salt of cation Xn+ of valency n, the counter ion being separate from the anion Ym" of valency m; and

said composition B comprising in a cosmetically acceptable medium at least one salt of anion Ym" of valency m, the counter ion being separate from the cation Xn+ of valency n.

6. Method according to one of claims 1 to 5, where the alkali earth cation Xn+ is chosen from Magnesium and Calcium.

7. Method according to one of claims 1 to 6, where the transition metal cation Xn+ is chosen from Zinc, Manganese, Titanium and Iron.

8. Method according to any of claims 1 to 7, where the cation Xn+ is in the form of a water soluble salt, preferably is chosen from halides, sulfates and carboxylates.

9. Method according to any of claims 5 to 8, where the salt of cation Xn+ is chosen from Calcium chloride, Magnesium chloride, Calcium pidolate, Calcium aspartate, Calcium gluconate, Calcium glutamate, Calcium heptagluconate, Calcium propionate, Calcium 2-cetogluconate, Calcium lactate, Calcium ascorbate, Calcium citrate, Magnesium acetate, Magnesium pidolate, Magnesium gluconate, Magnesium glutamate, Magnesium heptagluconate, Magnesium 2-cetogluconate, Magnesium lactate, Magnesium ascorbate, Magnesium citrate, Magnesium aspartate, Manganese gluconate and Magnesium sulfate.

10. Method according to claim 9, where the salt of cation Xn+ is chosen from Calcium chloride, Magnesium chloride, Calcium acetate and Magnesium lactate.

11 . Method according to any of claims 1 to 10, where the anion Ym" is chosen from hydrogenophosphate and hydrogenocarbonate.

12. Method according to any of claims 1 to 1 1 , where the anion Ym" is in the form of a salt preferably chosen from:

- alkali metal salts such as potassium or sodium, and

- ammonium salts, such as alkanolamine salts comprising one to three C C4 hydroxyalkyl radicals, identical or not.

13. Method according to any of claims 1 to 12, where the anion Ym" is in the form of an alkali metal salt, in particular a sodium or potassium salt.

14. Method according to one of claims 1 to 13, where the anion Ym" is in the form of a salt chosen from Na2C03, K2C03, NaHC03, KHC03, Na3P03, Na2HP04,

NaH2P04, Na2H2P207, Na4P207, K2HP04, KH2P04, K2H2P207, K4P207, Na2S04, MgS04, K2S04 and preferably NaHC03 and K2HP04.

15. Method according to any of claims 1 to 14, where the molar ratio between the cation Xn+ and the anion Ym" varies from 10 :1 to 1 :10 and more preferably from

4 :1 to 1 :4.

16. Method according to any of claims 3 to 15, where the total concentration in cation Xn+ and in anion Ym" varies from 1 to 70% by weight and more preferably from 2 to 50% by weight of the total weight of the compositions A and B.

17. Method according to any of claims 1 to 1 6, where the modulating agent is chosen from the complexing agents of the cation Xn+.

18. Method according to any of claims 1 to 17, where the modulating agent is chosen from:

- the mono or polycarboxylic acids, optionally hydroxylated, in free or salified form, such as propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid,

- the amino carboxylic acids in free or salified form such as aspartic acid, glutamic acid, serine, alanine, dehydroalanine and the oligomers thereof, iminosuccinic acid and the derivatives thereof, ethylene diamine tetraacetic acid,

- monosaccharides, oligosaccharides, polysaccharides and the derivatives thereof, preferably chosen from glucose, galactose, mannose, xylose, lyxose, fucose, arabinose, rhamnose, ribose, deoxyribose, quinovose, fructose, sorbose, talose, threose, erythrose, trehalose, lactose, maltose, cellobiose, glucuronic acid, lactobionic acid, alginates, chitosans and pectins,

- ascorbic acid,

- phytic acid,

- polymers or copolymers of carboxylic acids in free or salified form,

- polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid; polyglutamic acid,

- polymers or copolymers of maleic or itaconic acid, and

- polymers or copolymers of carboxymethylinulin.

19. Method according to claim 18, where the modulating agent is chosen from amino carboxylic acids in free or salified form, mono or polycarboxylic acids optionally hydroxylated in free or salified form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid, or the polymers or copolymers of carboxylic acids in free or salified form.

20. Method according to claim 18, where the modulating agent is chosen from citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid, in free or salified form, or a polymers or copolymers of carboxylic acids optionally amino.

21. Method according to any of claims 3 to 20, wherein the composition A comprising the cation Xn+ and the composition B comprising the anion Ym" are packaged separately and applied simultaneously or sequentially on the surface of the skin with an interval of time ranging from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour.

22. Cosmetic composition, in particular for the treatment of human perspiration and optionally body odors resulting from the perspiration, ready-to-use, that includes, in a cosmetically acceptable medium, at least one salt of cation Xn+ of valency n, at least one salt of anion Ym" of valency m and at least one modulating agent, said composition comprising less than 5% by weight in relation to the total weight of composition of aluminum salt, and said cation Xn+ being multivalent inorganic and chosen from:

(i) alkali earth cations, and

(ii) transition metal cations.